26.6 C
Vientiane
Friday, August 29, 2025
spot_img
Home Blog Page 383

Synopsys Completes Acquisition of Ansys

Creating the Leader in Engineering Solutions from Silicon to Systems

News Highlights:

  • Combines leaders in silicon design, IP and simulation and analysis to enable customers to rapidly innovate AI-powered products 
  • Now positioned to win in an expanded $31 billion total addressable market (TAM)1
  • Fast-tracking integrated technology roadmap, with first set of combined capabilities planned for the first half of 2026

SUNNYVALE, Calif., July 17, 2025 /PRNewswire/ — Synopsys (Nasdaq: SNPS) today announced the completion of its acquisition of Ansys. The transaction, which was announced on January 16, 2024, combines leaders in silicon design, IP and simulation and analysis to enable customers to rapidly innovate AI-powered products. Synopsys is now positioned to win in an expanded $31 billion total addressable market (TAM).1

Synopsys Completes Acquisition of Ansys
Synopsys Completes Acquisition of Ansys

“Today marks a transformational milestone for Synopsys. For decades, Synopsys has been delivering breakthroughs in silicon design and IP that have fueled chip innovation,” said president and CEO of Synopsys, Sassine Ghazi. “The increasing complexity of developing intelligent systems demands design solutions with a deeper integration of electronics and physics, enhanced by AI. With Ansys’ leading system simulation and analysis solutions now part of Synopsys, we can maximize the capabilities of engineering teams broadly, igniting their innovation from silicon to systems.”

Former Ansys president, CEO, and board member Ajei Gopal and former Ansys board member Ravi Vijayaraghavan are joining Synopsys’ board of directors, effective immediately.

“For half a century, Ansys has enabled innovators across industries to push boundaries with the predictive power of simulation and analysis,” said Gopal. “Our companies have a common culture, a successful longstanding partnership, and now a united mission to empower innovators to drive human advancement. I look forward to serving this mission as a member of the Synopsys board and expect a swift, successful integration.”

Synopsys remains dedicated to helping engineers innovate, reduce time-to-market and costs, and improve product quality by delivering unprecedented insights into how their products will perform in the real world. And, united with Ansys, Synopsys can now deliver holistic system design solutions for customers in industries spanning semiconductors, high-tech, automotive, aerospace, industrial, and more.

Synopsys expects to deliver the first set of integrated capabilities in the first half of 2026 that fuse multiphysics across the full EDA stack, including for multi-die advanced packaging. The combined roadmap also includes integrated solutions to advance testing and virtualization of complex, intelligent systems for automotive and other industries.

This combination bolsters Synopsys’ strong financial position with projected margin expansion and greater unlevered free cash flow generation, enabling rapid deleveraging over a period of two years. Ansys common stock will no longer be listed for trading on the NASDAQ stock market.

Other Resources

1

2023 TAM based on Synopsys management estimates

About Synopsys
Synopsys, Inc. (Nasdaq: SNPS) is the leader in engineering solutions from silicon to systems, enabling customers to rapidly innovate AI-powered products. We deliver industry-leading silicon design, IP, simulation and analysis solutions, and design services. We partner closely with our customers across a wide range of industries to maximize their R&D capability and productivity, powering innovation today that ignites the ingenuity of tomorrow. Learn more at www.synopsys.com

© 2025 Synopsys, Inc. All rights reserved. Synopsys, the Synopsys logo, and other Synopsys trademarks are available at https://www.synopsys.com/company/legal/trademarks-brands.html . Other company or product names may be trademarks of their respective owners.

Forward Looking Statements

This press release includes certain forward-looking statements within the meaning of the federal securities laws, including, but not limited to, statements that relate to our expected future business and financial performance, the anticipated benefits of the transaction, the anticipated impact of the transaction on the combined business, and the expected synergies from the transaction. These forward-looking statements generally are identified by the words “believe,” “project,” “expect,” “anticipate,” “estimate,” “intend,” “strategy,” “future,” “opportunity,” “plan,” “may,” “should,” “will,” “would,” “will be,” “will continue,” “will likely result,” and similar expressions or the negatives of these words or other comparable terminology to convey uncertainty of future events or outcomes. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks, uncertainties and other factors that could cause actual future events to differ materially from the forward-looking statements in this communication, including, but not limited to: (i) our ability to maintain relationships with Synopsys’ and Ansys’ customers, suppliers and other business partners; (ii) the effect of the transaction on our operating results and business; (iii) our ability to implement plans, forecasts, expected financial performance and other expectations with respect to the combined business and realize the expected benefits/synergies as well as manage the scope and size of the combined company; (iv) unexpected costs, charges and expenses related to the integration; (v) our ability to successfully integrate Ansys’ operations and product lines; (vi) difficulties in retaining and hiring key personnel and employees due to the integration; (vii) the diversion of management time on integration; (viii) our ability to manage significant indebtedness, including indebtedness incurred in connection with the transaction, and the need to generate sufficient cash flows to service and repay such debt; (ix) uncertainty in the macroeconomic and geopolitical environment and its potential impact on the semiconductor and electronics industries; (x) uncertainty in the growth of the semiconductor, electronics and artificial intelligence industries, (xi) the highly competitive industries we operate in; (xii) actions by the U.S. or foreign governments, such as the assessment of fines or the imposition of additional export restrictions or tariffs; (xiii) consolidation among our customers and within the industries in which we operate, as well as our dependence on a relatively small number of large customers; and (xiv) the evolving legal, regulatory and tax regimes under which we operate. 

Our filings with the Securities and Exchange Commission, which you may obtain for free at its website at http://www.sec.gov, discuss some of the important risk factors that may affect our business, results of operations and financial condition. Actual results may vary from the estimates provided. We undertake no intent or obligation to publicly update or revise any of the estimates and other forward-looking statements made in this announcement, whether as a result of new information, future events or otherwise, except as required by law.

Investor Contact:
Trey Campbell
Synopsys, Inc.
650-584-4289
Synopsys-ir@synopsys.com 

Editorial Contact
Cara Walker 
Synopsys, Inc. 
(650) 584-5000
corp-pr@synopsys.com

Synopsys
Synopsys

 

Co-PSMA trial: Recruitment successfully completed

SYDNEY, July 17, 2025 /PRNewswire/ — Clarity Pharmaceuticals (ASX: CU6) (“Clarity” or “Company”), a clinical-stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for patients with cancer, is pleased to announce that the Co-PSMA (NCT06907641)[1] Investigator-Initiated Trial (IIT) led by Prof Louise Emmett at St Vincent’s Hospital Sydney has now completed study enrolment, with all participants having been imaged.

The study is evaluating the performance of Clarity’s diagnostic product, 64Cu-SAR-bisPSMA, in comparison to standard-of-care (SOC) 68Ga-PSMA-11 for the detection of prostate cancer recurrence in patients with low prostate-specific antigen (PSA) who are candidates for curative salvage therapy.

Co-PSMA (Comparative performance of 64Copper [64Cu]-SAR-bisPSMA vs. 68Ga-PSMA-11 PET CT for the detection of prostate cancer recurrence in the setting of biochemical failure following radical prostatectomy) is a prospective, Phase II imaging trial in 50 patients in biochemical recurrence (BCR) of prostate cancer. Eligible patients were required to have had radical prostatectomy with no salvage therapy and a PSA between 0.2 and 0.75 ng/mL. The primary objective of the trial is to compare the detection rate of sites of prostate cancer recurrence, as determined by number of lesions per patient, between 64Cu-SAR-bisPSMA and 68Ga-PSMA-11 PET/CT.

The diagnostic capabilities of 64Cu-SAR-bisPSMA compared to SOC diagnostic imaging have been demonstrated in two prospective clinical trials, PROPELLER[2] and COBRA[3]. Following the positive results of these trials, Clarity is conducting two Phase III registrational trials, CLARIFY[4] and AMPLIFY[5], in the pre-prostatectomy and BCR settings, respectively. The CLARIFY trial is recruiting patients at St Vincent’s Hospital Sydney and this site will also open recruitment for the AMPLIFY trial shortly with Prof Emmett as the principal investigator.

Dr Alan Taylor, Executive Chairperson of Clarity Pharmaceuticals, commented: “We are excited about this important milestone in the Co-PSMA trial and the development program of 64Cu-SAR-bisPSMA. With mounting data of the benefits that 64Cu-SAR-bisPSMA could offer compared to SOC diagnostic imaging, demonstrated in the PROPELLER and COBRA trials, we eagerly anticipate the results from this head-to-head trial against 68Ga-PSMA-11.

“The high volume of patients imaged in recent months at a single site reflects the high unmet need for more effective diagnostic tools for men with rising PSA following radical prostatectomy. Visualising cancer early in these patients is crucial for physicians to determine the optimal course of treatment before the cancer spreads, leading to improved outcomes, including the potential for cure. We are very pleased to be able to support Prof Emmett, a world-renowned thought leader in the theranostics space, through the Co-PSMA trial in our own city of Sydney. We are honoured to continue working together on our pipeline of Targeted Copper Theranostics (TCTs) at St Vincents Hospital Sydney, as it is already actively recruiting patients for the CLARIFY trial and preparing to open enrolment for the AMPLIFY trial shortly.”

Prof Louise Emmett (St Vincent’s Hospital Sydney), Principal Investigator in the Co-PSMA trial, commented, “We are pleased to have reached our enrolment target for the Co-PSMA trial. Imaging prostate cancer patients has evolved significantly in recent years, particularly with the development of the current-generation PSMA targeted products. The approved PSMA PET products have high specificity, however, due to their low sensitivity, especially in patients with low PSA, a considerable proportion of patients have no detectable disease on the scans while their PSA continues to rise, indicating recurrence of their cancer. With no clear visualisation of where the cancer is located, planning effective treatments is challenging. Early intervention is essential in order to achieve cure in BCR, and the need for more sensitive diagnostics remains. This unmet need is what led us to design the Co-PSMA study.

“The data generated thus far on 64Cu-SAR-bisPSMA in the PROPELLER and COBRA trials are very encouraging. The high lesion uptake and retention of the product over time provides better visualisation on same-day imaging compared to SOC imaging. Furthermore, the delayed imaging, enabled by the longer half-life of copper-64 compared to gallium-68 and fluorine-18, increases image contrast, helping to identify smaller lesions and allowing more flexible scheduling of patients. If the Co-PSMA trial confirms that 64Cu-SAR-bisPSMA can detect more lesions than 68Ga-PSMA-11 in this patient group with such low PSA, this may improve image-guided therapy, potentially avoiding complications and improving outcomes. We look forward to reporting the trial results in the coming months.”

About SAR-bisPSMA

SAR-bisPSMA derives its name from the word “bis”, which reflects a novel approach of connecting two PSMA-targeting agents to Clarity’s proprietary sarcophagine (SAR) technology that securely holds copper isotopes inside a cage-like structure, called a chelator. Unlike other commercially available chelators, the SAR technology prevents copper leakage into the body. SAR-bisPSMA is a Targeted Copper Theranostic (TCT) that can be used with isotopes of copper-64 (Cu-64 or 64Cu) for imaging and copper-67 (Cu-67 or 67Cu) for therapy.

Disclaimer

64Cu-SAR-bisPSMA is an unregistered product. The safety and efficacy of 64Cu-SAR-bisPSMA has not been assessed by health authorities such as the US Food and Drug Administration (FDA) or the Therapeutic Goods Administration (TGA). There is no guarantee that this product will become commercially available.

About Prostate Cancer

Prostate cancer is the second most common cancer diagnosed in men globally and the fifth leading cause of cancer death in men worldwide[6]. Prostate cancer is the second-leading causes of cancer death in American men. The American Cancer Institute estimates in 2025 there will be about 313,780 new cases of prostate cancer in the US and around 35,770 deaths from the disease[7].

For more information, please contact:

Clarity Pharmaceuticals

Dr Alan Taylor

Lisa Sadetskaya

Executive Chairperson

Director, Corporate Communications

ataylor@claritypharm.com 

lisa@claritypharm.com 

References

1.  ClinicalTrials.gov Identifier: NCT06907641, https://clinicaltrials.gov/study/NCT06907641

2.  Eva Lengyelova et al. 64Cu-SAR-bisPSMA (PROPELLER) positron emission tomography (PET) imaging in patients with confirmed prostate cancer. JCO 41, 5039-5039(2023). DOI:10.1200/JCO.2023.41.16_suppl.5039

3.  Clarity Pharmaceuticals, https://www.claritypharmaceuticals.com/news/cobra_additional_results/

4.  ClinicalTrials.gov Identifier: NCT06056830, https://clinicaltrials.gov/ct2/show/NCT06056830

5.  ClinicalTrials.gov Identifier: NCT06970847, https://clinicaltrials.gov/study/NCT06970847

6.  Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries, https://acsjournals.onlinelibrary.wiley.com/doi/10.3322/caac.21660 

7.  American Cancer Society: Key Statistics for Prostate Cancer, https://www.cancer.org/cancer/prostate-cancer/about/key-statistics.html

This announcement has been authorised for release by the Executive Chairperson.

High-Trend International Group Held Extraordinary General Meeting for Share Capital Restructure

SINGAPORE, July 17, 2025 /PRNewswire/ — High-Trend International Group (the “Registrant” or the “Company”) (NASDAQ: HTCO), a global ocean technology company, held its Extraordinary General Meeting of Shareholders (the “Meeting”) on July 16, 2025. At the Meeting, the shareholders voted to approve (1) the proposal that effective immediately following the close of the Meeting, every 25 issued and unissued class A ordinary shares of a par value of US$0.0001 each and every 25 issued and unissued class B ordinary shares of a par value of US$0.0001 each in the Company’s existing share capital be consolidated into 1 class A ordinary share of a par value of US$0.0025 and 1 class B ordinary share of a par value of US$0.0025, respectively (each a “Consolidated Share”) and such Consolidated Shares shall rank pari passu in all respects with each other and have the rights and privileges and be subject to the restrictions as contained in the third amended and restated memorandum and articles of association of the Company (the “Share Consolidation”), so that immediately following the Share Consolidation, the authorized share capital of the Company shall be changed from US$50,000 divided into 497,500,000 class A ordinary shares of a par value of US$0.0001 each and 2,500,000 class B ordinary shares of a par value of US$0.0001 each, to US$50,000 divided into 19,900,000 class A ordinary shares of a par value of US$0.0025 each and 100,000 class B ordinary shares of a par value of US$0.0025 each; (2) the proposal that effective immediately following the close of the Meeting, the authorized share capital of the Company be increased by the creation of an additional 470,000,000 class A ordinary shares of a par value of US$0.0025 each and 10,000,000 class B ordinary shares of a par value of US$0.0025 each to rank pari passu in all respects with the existing class A ordinary shares and class B ordinary shares, respectively (the “Increase of Authorized Share Capital”) so that immediately following the Increase of Authorized Share Capital, the authorized share capital of the Company shall be changed from US$50,000 divided into 19,900,000 class A ordinary shares of a par value of US$0.0025 each and 100,000 class B ordinary shares of a par value of US$0.0025 each, to US$1,250,000 divided into 489,900,000 class A ordinary shares of a par value of US$0.0025 each and 10,100,000 class B ordinary shares of a par value of US$0.0025 each; and (3) the proposal that effective immediately following the close of the Meeting, the second amended and restated memorandum and articles of association of the Company currently in effect be amended and restated by the deletion in their entirety and the substitution in their place of the third amended and restated memorandum and articles of association annexed to the notice of the Meeting.

About High-Trend International Group

High-Trend International Group (“High-Trend” or the “Company”) is a global ocean technology company with businesses in international shipping and marine carbon neutrality. The Company connects the decarbonization needs of the maritime industry with the supply of the carbon finance market through technology ecosystem, creating a new paradigm for maritime sustainability.  

Forward Looking Statements

This announcement contains “forward-looking” statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These statements are made under the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical fact, including, without limitation, those with respect to the objectives, plans and strategies of the Company set forth herein and those preceded by or that include the words “believe,” “expect,” “anticipate,” “future,” “will,” “intend,” “plan,” “estimate” or similar expressions, are “forward-looking statements”. Such statements include, but are not limited to risks detailed in the Company’s filings with the U.S. Securities and Exchange Commission, including its Annual Report on Form 20-F for the fiscal year ended October 31, 2024. These forward-looking statements involve a number of risks and uncertainties, which could cause the Company’s future results to differ materially from those anticipated. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those indicated or anticipated by such forward-looking statements. All information provided in this press release is as of the date of the publication, and the Company does not undertake any obligation to update any forward-looking statement, except as required under applicable law.

 

ZAMST renews partnership with NBA Basketball Star Trae Young as Global Brand Ambassador

TOKYO, July 17, 2025 /PRNewswire/ — ZAMST, a global leader in premium sports bracing and support, proudly announces the renewal of its global brand ambassador partnership with NBA All-Star guard Trae Young of the Atlanta Hawks. This continued alliance marks a powerful milestone in a relationship that began in 2020, rooted in shared values of resilience, innovation, and peak performance.

Trae Young in action with the ZAMST A2-DX ankle brace
Trae Young in action with the ZAMST A2-DX ankle brace

“Zamst has been with me since the beginning – through every game and every step of the way. Their braces keep me protected and confident on the court, and I am honored to continue this relationship.” – Trae Young

Trae Young : Setting the standard in NBA  

The 2024–25 season marked another remarkable chapter for Young. Selected to his fourth NBA All-Star Game and finishing the season as top assist leader further cementing his status as one of the league’s premier playmakers. Widely recognized for his deep shooting range, clutch shot-making, and elite playmaking ability, Young continues to be a driving force at the point guard position.

Off the court, he is committed to mentorship and youth development, resonating with fans around the globe.

Engineered for Greatness: Trae & ZAMST

Zamst: “Trae’s exceptional performance, leadership within his team and commitment to community align perfectly with ZAMST’s mission to empower athletes to perform at their highest potential. His leadership on and off the court makes him an ideal ambassador, and we are honored to support him as he continues to inspire the next generation”

Since first teaming up with ZAMST, Young has trusted flagship A2-DX ankle braces —to maintain peak condition and protect himself during games. As a global brand ambassador, Young promotes the importance of injury prevention and proper conditioning for athletes of all levels.

Explore why Trae Young trusts the A2-DX:  https://www.youtube.com/watch?v=shqkbR7AHh0

Trae Young ankle brace and Zamst full support gear lineup
Trae Young ankle brace and Zamst full support gear lineup

ABOUT ZAMST

Zamst reinforces and protects athletes by providing premium and technical bracing products derived from innovative materials, designs and manufacturing processes. Created in 1992 by Nippon Sigmax Co., Ltd a leader in the Japanese orthopedic market, Zamst leverages its strong medical expertise to build products that maximize anatomical functionality and performance. Trusted over 30 years by elite athletes, Zamst continuously evolves to become the most authentic sports medicine and wellness brand in the industry.

The A2-DX is one of Zamst’s signature ankle braces, widely trusted by professional basketball organizations and athletes across collegiate, high school and club levels. Designed for high-impact sports, it provides strong support for the ankle without limiting mobility.

Discover more on Trae Young ankle braces and other Zamst products at: http://www.zamst.us

AI that works for everyone: TELUS proud to join the UN AI for Good Global Summit 2025

TELUS President and CEO, Darren Entwistle, and Chief Data & Trust Officer, Pam Snively, attended the United Nations AI for Good Global Summit as part of the AI Skills Coalition driving AI literacy globally; TELUS hosted an interactive workshop using Fuel iX demonstrating how to build ethical AI with intelligence from Indigenous Peoples

GENEVA, July 17, 2025 /PRNewswire/ — TELUS, a leading global technology company, participated in the United Nations AI for Good Global Summit 2025 from July 8 – 11 in Geneva, Switzerland, demonstrating its commitment to responsible AI development, ethical technology innovation and inclusive AI upskilling.

TELUS President and CEO, Darren Entwistle, and Chief Data & Trust Officer, Pam Snively, attended the United Nations AI for Good Global Summit, demonstrating the tech company’s commitment to building trust in technology and the digital world. Credit: International Telecommunication Union AI for Good
TELUS President and CEO, Darren Entwistle, and Chief Data & Trust Officer, Pam Snively, attended the United Nations AI for Good Global Summit, demonstrating the tech company’s commitment to building trust in technology and the digital world. Credit: International Telecommunication Union AI for Good

As part of its engagement across multiple high-profile sessions, TELUS contributed as a proud member of the International Telecommunication Union (ITU)-led AI Skills Coalition – a global initiative to close the AI skills gap – supporting efforts that ITU Secretary-General Doreen Bogdan-Martin says, aim to ensure “the AI Generation will be defined not by the power of its algorithms, but by the depth of its skillset… and the breadth of its participation.”

TELUS engaged in multiple high-profile sessions throughout the five-day summit, sharing insights on responsible AI practices, the value of AI literacy and best practices around AI governance. The Canadian company’s long-standing approach to human-centric technology development is highly collaborative among its industry, community and team stakeholders, supporting innovative AI development and use that has a positive social impact.

“At TELUS, we believe getting AI right starts with trustworthy, transparent and respectful data practices. Realizing AI’s potential for positive change is only possible by earning the trust of the people it’s meant to serve and that means leading with a human-centric approach,” said Pamela Snively, Chief Data & Trust Officer at TELUS. “We’re proud to have joined other global leaders at the AI for Good Summit because we recognize that responsible AI practices and principles, industry collaboration and community partnerships are the foundation for AI innovation that benefits humanity.”

Building on its commitment to working in close partnership with Indigenous Peoples to help deliver positive social, cultural and economic outcomes through connectivity, TELUS collaborated with Shani Gwin, founder and CEO of pipikwan pêhtâkwan and TELUS Indigenous Advisory Council member, to deliver a workshop titled, “Crafting ethical AI with Indigenous intelligence: Partnering with Indigenous Peoples for innovative solutions”. The workshop demonstrated how TELUS is using AI to create meaningful business practices and technology informed by Indigenous Peoples. The session also included hands-on AI literacy training using TELUS Digital’s proprietary generative AI platform, Fuel iX™, as well as pipikwan pêhtâkwan’s AI tool, wâsikan kisewâtisiwin to correct unconscious bias toward Indigenous Peoples online.

TELUS has consistently demonstrated its commitment to reconciliation with Indigenous Peoples in Canada through an action plan with the goal of creating positive social and economic outcomes. These actions include partnering with Indigenous communities on connectivity, training and job creation programs; supporting land restoration initiatives; safeguarding Indigenous data and artistic integrity; and more. In its recent 2025 AI Report, TELUS captured perspectives on AI from over 5,500 respondents, with specific focus given to engaging with Indigenous Peoples, including First Nations, Inuit, and Métis, and other underrepresented* groups. It highlighted the importance of integrating Indigenous perspectives into responsible AI. Through workshops and discussions with Indigenous Peoples, the report reveals that Indigenous Knowledge, including storytelling and other qualitative data, are as important as quantitative data, and that without these forms of Indigenous Knowledge, context or meaning risk being lost through AI model processing.

TELUS’ participation in the Summit builds on its established leadership in responsible AI development, including being the first company globally to achieve ISO 31700-1 Privacy by Design certification for its generative AI customer support tool, powered by Fuel iX. The company was the first Canadian company to embrace the Hiroshima AI Process (HAIP) Reporting Framework, sharing its proven approaches and best practices for safe and trustworthy AI development in alignment with the G7 AI Code of Conduct, and it was the first telecom company in Canada to sign the Government of Canada’s voluntary code of conduct for GenAI. In March 2025, TELUS announced that it is launching a series of Sovereign AI Factories, providing Canadian businesses and researchers with advanced technology to drive innovation, while keeping all data and computing power in Canada. Importantly, TELUS’ AI Factory is built in one the world’s most sustainable AI-ready data centres in Rimouski, Quebec. It utilizes 99% renewable energy and is three times more energy efficient for excess power usage than the industry average. TELUS continues to pioneer AI practices that prioritize transparency, accountability and trust.

For more information about TELUS’ commitment to building trust in data, visit telus.com/trust.

*According to the Government of Canada’s mandate on research design, “underrepresentation refers generally to groups or individuals from groups who, due to both formal and legal restrictions and to systemic barriers, have lacked access to full participation in a given organization, community or discipline.”

About TELUS

TELUS (TSX: T, NYSE: TU) is a world-leading communications technology company operating in more than 45 countries and generating over $20 billion in annual revenue with more than 20 million customer connections through our advanced suite of broadband services for consumers, businesses and the public sector. We are committed to leveraging our technology to enable remarkable human outcomes. TELUS is passionate about putting our customers and communities first, leading the way globally in client service excellence and social capitalism. Our TELUS Health business is enhancing more than 150 million lives across 200 countries and territories through innovative preventive medicine and well-being technologies. Our TELUS Agriculture & Consumer Goods business utilizes digital technologies and data insights to optimize the connection between producers and consumers. Guided by our enduring ‘give where we live’ philosophy, TELUS, our team members and retirees have contributed $1.8 billion in cash, in-kind contributions, time and programs including 2.4 million days of service since 2000, earning us the distinction of the world’s most giving company. For more information, visit telus.com or follow @TELUSNews on X and @Darren_Entwistle on Instagram.

About ITU
The International Telecommunication Union (ITU) is the United Nations agency for digital technologies, driving innovation for people and the planet with 194 Member States and a membership of over 1,000 companies, universities, civil society, and international and regional organizations. Established in 1865, ITU coordinates the global use of the radio spectrum and satellite orbits, establishes international technology standards, drives universal connectivity and digital services, and is helping to make sure everyone benefits from sustainable digital transformation, including the most remote communities. From artificial intelligence (AI) to quantum, from satellites and submarine cables to advanced mobile and wireless broadband networks, ITU is committed to connecting the world and beyond. Learn more:  www.itu.int

Media contact
Emily Piccinin
TELUS Public Relations
emily.piccinin@telus.com 

 

Solace Announces Availability of Solace Agent Mesh in the new AWS Marketplace AI Agents and Tools Category

OTTAWA, ON, July 17, 2025 /PRNewswire/ — Solace, the leader in powering real-time, event-driven integration for the agentic age, today announced the availability of Solace Agent Mesh in the new AI Agents and Tools category of AWS Marketplace. Customers can now use AWS Marketplace to easily discover, buy, and deploy Solace’s event-driven agentic AI platform using their AWS accounts, accelerating AI agent and agentic workflow development.

Solace Agent Mesh enables organizations to seamlessly integrate and orchestrate all of its AI agents and other assets in real-time with the power of event-driven integration.

“We’re excited to offer Solace Agent Mesh in the new AI Agents and Tools category in AWS Marketplace,” said Tim Wong, Chief Revenue Officer at Solace. “AWS Marketplace provides a streamlined way for customers to access our agentic framework, helping them to build and deploy intelligent, extensible, and well-governed AI-powered applications.”

Unlike legacy request-response integration models, Solace Agent Mesh routes inputs through an intelligent orchestrator that breaks down events into tasks and dispatches them to appropriate AI agents in real-time, helping organizations fully embrace the benefits of agentic AI:

  • Time to innovation – easily integrate new AI agents and orchestrate interactions between them
  • User experience – improve user experiences by ensuring agents have access to real-time data
  • Scalability & reliability – enable asynchronous, event-driven communication between agents, other applications and data sources
  • Operational efficiency – streamline complex workflows and eliminate manual processes that slow down AI-based applications
  • Security & governance – ensure compliance and governance with robust authentication, authorization and role-based access

With the availability of AI Agents and Tools in AWS Marketplace, customers can significantly accelerate their procurement process to drive AI innovation, reducing the time needed for vendor evaluations and complex negotiations. With centralized purchasing using AWS accounts, customers maintain visibility and control over licensing, payments, and access through AWS.

Learn more about Solace Agent Mesh and the new AI Agents and Tools category in AWS Marketplace.

About Solace:

Solace helps enterprises adopt AI by enabling real-time, event-driven integration across their entire business. Built on a modern event-driven architecture, Solace Platform connects systems, applications, and AI agents with the data they need — securely, seamlessly, and at scale. Established enterprises worldwide – including RBC Capital Markets, Heineken, PSA Singapore and Schwarz Group – trust Solace to enable time-sensitive applications and processes; modernize their application and integration landscape; and create seamless digital experiences for their customers, partners and employees. Learn more at solace.com.

Press Contacts

Europe & Americas

UK

APAC

IBA International

Positive

Rice Communications

Jamie Kightley

Daniel Brown

Trixie Wong

Jkightley@iba-international.com

dbrown@positivemarketing.com

trixie.wong@ricecomms.com

+44 (0) 1572 757932

+44 7480 924144

+65 9757 7531

 

Winners in 2025 Stevie® Awards for Great Employers Announced

Winners to Be Celebrated in New York on September 16

FAIRFAX, Va., July 17, 2025 /PRNewswire/ — Winners in the 2025 (10th annual) Stevie® Awards for Great Employers were announced today. The awards recognize the world’s best employers and the human resources professionals, teams, achievements, and HR-related products and suppliers who help to create and drive great places to work. 

Winners in the 2025 (10th annual) Stevie® Awards for Great Employers were announced today. The awards recognize the world’s best employers and the human resources professionals, teams, achievements, and HR-related products and suppliers who help to create and drive great places to work.
Winners in the 2025 (10th annual) Stevie® Awards for Great Employers were announced today. The awards recognize the world’s best employers and the human resources professionals, teams, achievements, and HR-related products and suppliers who help to create and drive great places to work.

Among the organizations with five or more Stevie wins are Bank of America (14), DP DHL (14), Globe Telecom (14), Tata Consultancy Services (13), Cathay United Bank (12), Apexon (11), IBM (11), Enerjisa Enerji (10), MGM China (10), PEGASUS AIRLINES (10), pladis (9), Allianz SE (8), Zenutna Holdings Corporation (8), DIMES (7), Ooredoo (7), PLDT and Smart (6), American Health Marketplace (5), Benifex (5), Eren Enerji (5), Everise (5), Gcash (5), HAVELSAN A.Ş. (5), Limak Cement (5), Saman Bank (5), and Türkiye Kalkınma ve Yatırım Bankası (5).

For a full list of winners by category, visit https://www.StevieAwards.com/HR.

Two Grand (“best of show”) trophy winners in the competition will be announced during the week of July 28.

Winners will be celebrated during a ceremony on Tuesday, September 16 at the Marriott Marquis Hotel in New York City. Tickets are now on sale. The presentations will be broadcast live.

More than 1,000 nominations from organizations in 35 nations and territories were evaluated in this year’s competition. Winners were determined by the average scores of more than 115 professionals worldwide, acting as judges. The Stevie Awards for Great Employers recognize achievement in many facets of the workplace. Category groups include:

  • Employer of the Year Categories
  • HR Achievement Categories
  • HR Individual Categories
  • HR Team Categories
  • Solution Provider Categories
  • Solutions, Implementations, and Training Programs or Media Categories
  • Thought Leadership Categories

Stevie Award placements in the 31 Employer of the Year categories were determined by a unique blending of the ratings of judging professionals and more than 130,000 votes of the general public.

The awards are presented by the Stevie Awards, which organizes nine of the world’s leading business awards programs including the prestigious International Business Awards® and The American Business Awards®.

About the Stevie Awards

Stevie Awards are conferred in nine programs: the Asia-Pacific Stevie Awards, the German Stevie Awards, the Middle East & North Africa Stevie Awards, The American Business Awards®, The International Business Awards®, the Stevie Awards for Women in Business, the Stevie Awards for Great Employers, the Stevie Awards for Technology Excellence, and the Stevie Awards for Sales & Customer Service. Stevie Awards competitions receive more than 12,000 entries each year from organizations in more than 70 nations. Honoring organizations of all types and sizes and the people behind them, the Stevies recognize outstanding performances in the workplace worldwide. Learn more about the Stevie Awards at http://www.StevieAwards.com.

Marketing Contact:

Nina Moore
Nina@StevieAwards.com
703 547 8389

RapidClaims Receives Frost & Sullivan’s 2025 North American Healthcare IT-Software and Services Technology Innovation Leadership Recognition for Excellence in AI-Driven RCM Automation

Recognized for driving operational efficiency and accelerating customer acquisition through AI-powered automation and a highly adaptive deployment model

SAN ANTONIO, July 17, 2025 /PRNewswire/ — Frost & Sullivan is pleased to announce that RapidClaims has been recognized with the 2025 North American Healthcare IT-Software and Services Technology Innovation Leadership Recognition in the healthcare IT industry for its outstanding achievements in product innovation, operational excellence, and customer-centric design in the revenue cycle management (RCM) space. This recognition highlights RapidClaims’ consistent leadership in driving measurable outcomes, strengthening its market position, and delivering customer-centric innovation in an evolving competitive landscape.

Frost & Sullivan evaluates companies through a rigorous benchmarking process across two core dimensions: strategy effectiveness and strategy execution. RapidClaims excelled in both, demonstrating its ability to align strategic initiatives with market demand while executing them with efficiency, consistency, and scale.

“RapidClaims boosts customer stickiness through a highly adaptive deployment model. Clients can integrate the platform into existing infrastructure with minimal disruption through comprehensive enterprise rollouts or modular, specialty-focused implementations,” said Sagar Mukhekar, Industry Analyst, Growth Opportunity Analytics, Frost & Sullivan.

Guided by a long-term growth strategy focused on AI-powered automation, a robust integration ecosystem, and a highly adaptive deployment model, RapidClaims has shown its ability to adapt and lead in a rapidly evolving landscape. The company’s strategic agility and sustained investment in advanced technologies have enabled it to scale effectively across healthcare organizations of varying sizes and specialties. Innovation remains central to RapidClaims’ approach. Its suite of products—RapidCode™, RapidScrub™, and RapidCDI™—automates complex RCM functions, such as medical coding, claim scrubbing, and denial management, while supporting both modular and full-suite implementations. These solutions combine proprietary AI models trained on healthcare-specific datasets with configurable rule engines that deliver measurable gains in accuracy, speed, and adaptability.

RapidClaims’ unwavering commitment to customer experience further strengthens its position in the market. The platform offers highly configurable data ingestion, guideline implementation, and workflow customization to meet the unique needs of each client and specialty. Its rapid deployment model enables seamless integration into existing IT infrastructures with minimal disruption, enhancing customer stickiness and long-term value. By providing scalable commercial options, RapidClaims is positioned to accelerate customer acquisition while ensuring superior performance and client satisfaction.

“Healthcare is at the crossroads with most provider organizations wanting to do more for their patients as well as care teams, and this is exactly where technology should support. Talk to any doctor or healthcare CFO, they are more than open to explore what AI can do for them as long as we keep the buzzwords away. That’s exactly what we champion at RapidClaims: no-fuss, quantifiable solutions aimed at eliminating long-standing inefficiencies in RCM operations in their entirety,” said Dushyant Mishra, Cofounder & CEO at RapidClaims. “We are delighted to be judged as a leader by F&S for the real-world outcomes we deliver, and validations like these push us further in our cause of achieving a reality of 0% claims denial,” he added.

Frost & Sullivan commends RapidClaims for setting a high standard in competitive strategy, execution, and market responsiveness. The company’s vision, innovation pipeline, and customer-first culture are shaping the future of the healthcare IT industry and driving tangible results at scale.

Each year, Frost & Sullivan presents the Technology Innovation Leadership Recognition to a company that demonstrates outstanding strategy development and implementation, resulting in measurable improvements in market share, customer satisfaction, and competitive positioning. This recognizes forward-thinking organizations that are reshaping their industries through innovation and growth excellence.

Frost & Sullivan Best Practices recognitions honor companies in various regional and global markets for demonstrating outstanding achievement and superior performance in leadership, technological innovation, customer service, and strategic product development. Industry analysts compare market participants and measure performance through in-depth interviews, analyses, and extensive secondary research to identify best practices in the industry.

About Frost & Sullivan

For six decades, Frost & Sullivan has been world-renowned for its role in helping investors, corporate leaders, and governments navigate economic changes and identify disruptive technologies, megatrends, new business models, and companies to action, resulting in a continuous flow of growth opportunities to drive future success. Contact us: Start the discussion.

Contact:

Camila Tinajero
E: camila.tinajero@frost.com

About RapidClaims

RapidClaims is a NY-based, Accel-backed healthcare technology company on a mission to transform healthcare revenue cycle management through intelligent automation and data-driven insights. Serving leading health systems and provider groups nationwide, the company’s AI-powered platform streamlines billing workflows and captures lost revenue opportunities. RapidClaims’ products deliver a 10% revenue uplift, cut claim denials by up to 30%, and reduce administrative workload more than 50%, freeing physicians to spend more time on direct patient care. Designed for seamless integration, RapidClaims supports all major EHR systems and adheres to industry standards like FHIR and HL7, ensuring interoperability and rapid deployment across diverse healthcare environments. For more information, visit rapidclaims.ai.

Contact:

Prakhar Mohan
E: prakhar@rapidclaims.ai
M: +1 (917) 722-0941